Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer
NCT ID: NCT05097417
Last Updated: 2021-10-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
110 participants
INTERVENTIONAL
2021-11-01
2024-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
traditional Chinese medicine combined with thermal or cold ablation
traditional Chinese medicine and ablation in the primary tumor sites
Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
thermal or cold ablation
ablation
Patients will be treated with ablation in the primary tumor sites
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
traditional Chinese medicine and ablation in the primary tumor sites
Patients will be treated with traditional Chinese medicine and ablation in the primary tumor sites
ablation
Patients will be treated with ablation in the primary tumor sites
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with lung nodule.
* Maximum diameter of lung nodule ≥8mm.
* The pathology of lung nodules biopsy was non-small cell lung cancer.
* I period according to the eighth edition of the TNM staging period.
* No mediastinal lymph node metastasis.
* Eastern Cooperative Oncology Group performance status of 0 to 1.
* No prior anticancer treatments including surgery, radiation,chemotherapy or local treatments.
* Sufficient organ functions.
Exclusion Criteria
* Women during pregnancy or breast-feeding.
* Patients with severe heart, lung, kidney disease or other systemic diseases
* Patients with severe hemorrhagic diseases.
* Patients with a history of drug abuse or mental illness.
* Other conditions that the investigator has determined are not suitable for participation in this study
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ming Li
senior doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai 10th People's Hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lihong Fan, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021SH10
Identifier Type: -
Identifier Source: org_study_id